Alpha Teknova, Inc. (TKNO)

In Q2 2025, Alpha Teknova reported a 7% increase in total revenue compared to Q2 2024, driven by demand for critical reagents. In Q3 2025, revenue increased by 9% compared to Q3 2024, driven by growth in Lab Essentials products, though Clinical Solutions revenue decreased. TKNO shares gained 27% by September 25, 2025, but have shown volatility. As of November 27, 2025, the stock traded at $4.65. Analysts have a "Moderate Buy" consensus rating with a price target of $10.00.

Lab Essentials have shown consistent revenue growth, suggesting stable demand. Clinical Solutions demand has experienced softness but is expected to grow as therapies and diagnostics move towards commercialization. Fluctuations in biotech funding could impact demand for custom products, as approximately 25% of total revenue is derived from purchases of custom products by biopharma customers. The company aims for 20% to 25% long-term top-line expansion as clinical and diagnostic customers advance toward commercialization, indicating an expectation of growing demand in these areas.

Alpha Teknova, Inc. is a biotechnology company specializing in the development, manufacture, and distribution of reagents and solutions for the life sciences market. Founded in 1996 and headquartered in Hollister, California, the company serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. Its primary products include pre-poured media plates, liquid cell culture media and supplements, molecular biology reagents, lab essentials, and clinical solutions.

Alpha Teknova, Inc. primarily derives its key revenue from the United States. The company produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Alpha Teknova's brand is well-established in the life sciences industry, built on delivering high-quality, custom products and providing superior customer service. The company's ability to offer customer-specified Research Use Only (RUO) and Good Manufacturing Practice (GMP) formulations with short turnaround times, coupled with its technical expertise, differentiates it from competitors. No specific negative events impacting its brand reputation in the past year were highlighted.

Alpha Teknova is owned by a mix of institutional shareholders, insiders, and retail investors. Major shareholders include Telegraph Hill Partners IV LP, Ted Davis and Irene Davis, UBS Group AG, Balyasny Asset Management LP, Roubaix Capital LLC, BlackRock Inc, Vanguard Group Inc, J. Matthew MacKowski, and Conestoga Capital Advisors LLC.